LFG x Neuralink
Terms
Valuation: $8.5B (pre-money)
Total Raise: $500M
Structure: Primary
Our co-investment partner has direct access to the primary fundraising round based on a strategic partnership.
Our SPV will invest into a vehicle managed by our co-investment partner.
Management Fee: (one-time, upfront)
Non-Member: 10%
LFG+ Member: 6%
Carry:
Non-Member: 20%
LFG+ Member: 15%
Timeline
Commitment: submit your desired amount by Friday, May 9th
Closing: funds will be due on/around Wednesday, May 21st
Notes
Terms: please note that while we believe these will be the final terms, they may change due to factors beyond our control as the company finalizes allocations with partners.
LFG+ Membership: here are our membership details
Tiered Economics: contact us for reduced economics on checks over $500k
Management Fee: instead of charging an annual Management Fee, we handle it as a one-time, upfront (non-refundable) fee to simplify accounting and cap expenses. We apply the management toward administrative expenses, which are often charged separately by funds.
Limited Allocation: due to high demand, we anticipate that this allocation will be heavily oversubscribed before the deadline. We will make efforts to honor desired commitment amounts, but cannot guarantee full allocations. LFG+ Members will get priority.
Limited Information: given the sensitive nature of this deal, we will be limited in the information that we can share.
Click to Commit
About Neuralink
Neuralink, a pioneer in brain-computer interfaces (BCIs), is developing technology to connect human brains with computers, addressing neurodegenerative disorders and potentially enhancing cognitive capabilities. With the BCI market projected to grow from $2 billion in 2024 to $6 billion by 2030, driven by demand for treatments for paralysis and other neurological conditions, Neuralink is well-positioned to lead this emerging field. At its current valuation, Neuralink offers a compelling investment opportunity for those seeking exposure to a high-growth, transformative technology.
1. Founder: Elon Musk
Elon Musk’s track record as a serial entrepreneur underpins Neuralink’s potential. He has built some of the most transformative companies of our time: PayPal ($63B), Tesla ($888B, leading the EV market), SpaceX (~$350B, pioneering reusable rockets and space infrastructure), and xAI Holdings (valued at ~$113B, merging X’s real-time platform with cutting-edge AI models). Across each venture, Musk has consistently scaled disruptive technologies into category-defining giants. Neuralink benefits not just from his vision, but from the cross-company synergies — including AI advancements from xAI — positioning it to fundamentally reshape human-computer interaction.
2. Momentum: Human Trials Underway
Neuralink’s R1 surgical robot, which implants ultra-thin threads for precise brain interfacing, received FDA approval for human trials in May 2023. In January 2024, the first patient, with quadriplegia, used Neuralink’s BCI to control a computer cursor via thought alone. As of April 2025, three patients in the PRIME trial, targeting spinal cord injuries and ALS, have received implants, with plans for 20-30 more this year. These milestones mark steady progress toward scalable BCI applications.
3. Use Cases: Life-Changing
Neuralink’s current focus is enabling patients with paralysis or ALS to control devices through thought, as demonstrated in human trials and earlier monkey experiments (2020-2021), where subjects played games like Pong using BCIs. Elon Musk envisions broader applications, including treating depression, enhancing memory, or enabling cognitive enhancements like direct web access.